Ukrainian government unit sues in USA, alleging corrupt scheme in vaccine purchases

20 September 2010

A unit of the government of Ukraine last week filed suit in federal court in Portland, Oregon, USA, against a US company that is alleged to be part of an international conspiracy involving the fraudulent sale of vaccines and other pharmaceuticals.

The case was brought by Ukrvaktsina - the Ukrainian state-owned enterprise responsible for the procurement and storage of medicines and medical supplies for Ukraine's Ministry of Health. The suit seeks damages for fraud, conspiracy and violations of the Racketeer Influenced and Corrupt Organizations Act ("RICO").

The complaint alleges that, from 2008 through 2009, the US company Olden Group, which is owned by offshore companies registered in Belize and the South Pacific island of Niue, played a key role in a conspiracy to unlawfully mark-up the price of millions of doses of vaccines which were intended for use in the Ukrainian public health system. According to the complaint, Olden and the other conspirators used offshore shell companies to launder the cash proceeds of the scheme through banks in Latvia, the USA and elsewhere. The scheme is alleged to have involved more than $50 million in payments by Ukrvaktsina and the government of Ukraine over a period of several years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical